Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03254368 | Study to Assess the Effects and Safety of ZGN-1061 in Overweight and Obese Participants With Type 2 Diabetes | PHASE2 | COMPLETED | 188 | — | — | Sep 12, 2017 | Feb 22, 2019 | May 24, 2019 | 23 | Australia, New Zealand |
| Arm | Type | Description |
|---|---|---|
| 0.05 mg ZGN-1061 (A) | EXPERIMENTAL | 0.05 mg ZGN-1061 subcutaneous injection once every 3 days |
| 0.3 mg ZGN-1061 (B) | EXPERIMENTAL | 0.3 mg ZGN-1061 subcutaneous injection once every 3 days |
| 0.9 mg ZGN-1061 (C) | EXPERIMENTAL | 0.9 mg ZGN-1061 subcutaneous injection once every 3 days |
| 1.8 mg ZGN-1061 (CC) | EXPERIMENTAL | 1.8 mg ZGN-1061 subcutaneous injection once every 3 days |
| Placebo (D) | PLACEBO_COMPARATOR | Placebo subcutaneous injection once every 3 days |
| Name | Type | Description |
|---|---|---|
| ZGN-1061 | DRUG | ZGN-1061 is a methionine aminopeptidase 2 inhibitor |
| Placebo | DRUG | Placebo has the same excipients and appearance as ZGN-1061 |
Inclusion Criteria: Subjects must meet the following criteria to participate in this study: * Be between the ages of 18 and 70 years, inclusive. * Overweight or obese with a body mass index of at least 27 kg/m². * Have type 2 diabetes with HbA1c between 7% and 11%. * For subjects taking approved a...